Study: Selumetinib promotes radioiodine absorption in thyroid cancer

02/13/2013 | MedPage Today (free registration)

A new kinase inhibitor called selumetinib made advanced thyroid cancer more susceptible to radioiodine, especially in patients with RAS mutations in their disease, according to a study published in the New England Journal of Medicine. The drug restored or increased the absorption of iodine in 12 of 20 patients who were previously resistant to radioiodine, according to findings on PET images. "These results provide a proof of principle that MEK inhibitors can induce iodine uptake and retention in thyroid tumors," researchers said.

View Full Article in:

MedPage Today (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Actuarial Services, Government Programs
PacificSource
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC